Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents

Autor: Piet Maes, Martin Schwemmle, Allison Turner, Annette Ohnemus, Wander Van Breedam, Greetje Vande Velde, Bert Schepens, Sieglinde De Cae, Suzanne J.F. Kaptein, Nick Devoogdt, James Heads, Mark Ellis, Peter Staeheli, Gitte Michielsen, Bruno Dombrecht, Julius Beer, Dominique Tersago, Robbert Boudewijns, Sofie Jacobs, Leen Delang, Dries Van Herpe, João Paulo Portela Catani, Dirk Jochmans, Alistair Henry, Rana Abdelnabi, Nico Callewaert, Birgit Weynand, Sandrine Vanmarcke, Sarah Creytens, Simon Devos, George D. Moschonas, Isabel Remory, Annelies Van Hecke, Lana Langendries, Daniel Schnepf, Catelijne Stortelers, Koen Sedeyn, Ana Filipa Oliveira, Laura Seldeslachts, Xin Zhang, Xavier Saelens, Loes van Schie, Laurens Liesenborghs, Dorien De Vlieger, Chiara Lonigro, Frank Peelman, Massimiliano Germano, Joana Rocha-Pereira, Kevin Brady, Wannes Weyts, Hendrik Jan Tibaut, Sebastiaan ter Horst, Kai Dallmeier, Hannah Eeckhaut, Jackeline Cecilia Zavala Marchan, Kenny Roose, Johan Neyts, Wim Nerinckx, Daria Fijalkowska, Andy Popplewell, Iebe Rossey, Caroline Shi-Yan Foo, Jimmy Borloo

We have identified camelid single-domain antibodies (VHHs) that cross-neutralize SARS-CoV-1 and −2, such as VHH72, which binds to a unique highly conserved epitope in the viral receptor-binding domain (RBD) that is difficult to access for human ant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d213f47d21cc67cf73c8fd52a12112a4
https://doi.org/10.1101/2021.03.08.433449